Topic Listing for Avalon Pharmaceuticals

Amendments Articles Incorporation Bylaws Change Annual Cash Bonus
Annual Report Form 10-k Antibody Development
Appointment Independent Registered Public Accounting Firm Astrazeneca Plc
Attendance Annual Meeting Audit Committee
Audit Committee Financial Expert Audit Fees
Audit-related Fees Aurora Centrosome Pathway Program
Aurora Kinase Program Aurora Pathway Program
Available Information Avalon Pharmaceuticals Inc
Avn944 Program Award Agreement
Award Eligibility Limitations B-catenin Program
Base Salary Basic Diluted Net Loss Attributable Common Stockholders Per
Because Limited Operating History Amount Information Evaluate Business Because Obtain Regulatory Approval Market Drug Candidates United
Benchmarking Beneficial Ownership Reporting Compliance
Board Directors Business Involves Animal Testing Changes Laws Regulations Accepted
Cash Equivalents Catenin Program
Cautionary Advice Regarding Forward-looking Statements Certification Pursuant 302 Sarbanes-oxley Act 2002 Avalon Pharmaceuticals
Change Control Severance Benefits Changes Internal Control Over Financial Reporting
Chemdiv Inc Chemical Library Insufficient Meet Needs
Code Ethics Collaborative Relationships
Common Stock Compared 2004
Compared 2004 2003 Compared 2005
Compared 2006 Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Directors Compensation Mix
Compensation Philosophy Competition
Comprehensive Loss Conclusion Regarding Effectiveness Disclosure Controls Procedures
Consent Independent Registered Public Accounting Firm Consulting Agreements
Contractual Obligations Conversion Preferred Stock
Corporate Goals Objectives Corporate Governance
Costs Associated Exit Disposal Activities Credit Arrangements
Critical Accounting Policies Significant Judgments Estimates Deadline Submission Stockholder Proposals Next Annual Meeting
Deferred Financing Costs Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Development-stage
Disclosure Controls Procedures Dividends
Documents Incorporated Reference Drug Discovery Development Programs
Drug Discovery Methods Employ Through Avalonrx New Unproven Drug Discovery Technology Not Patented Value Candidates Adversely
Effect Changes Capitalization Election Directors
Employees Employment Agreements
Employment Agreements Indemnification Entry Material Definitive Agreement
Equipment Financing Equity Compensation Plan Information
Estimates Even Drug Candidates Obtain Regulatory Approval Subject Ongoing
Exact Name Registrant Specified Charter Executive Compensation Tables
Executive Officers Face Intense Competition Development Commercialization Drug Candidates
Face Liability Claims Related Misuse Drug Candidates Clinical Fail Enter New Strategic Collaborations Existing Terminated Not
Fail Enter New Strategic Collaborations Not Grow Revenue Fair Value Financial Instruments Concentration Credit Risk
Federal Income Tax Consequences Financial Operations Overview
Financial Statements Exhibits Foreign Regulation
Form 10-k Form Payment Options Restricted Stock
Future Collaborators Not Obtain Favorable Reimbursement Rates Drug General Administrative
Hatch-waxman Act Healthcare Reform Cost Control Initiatives Third-party Payors Reduce
Held 2007 Held 2008
History Losses Expect Continue Incur Foreseeable Future Never Hsp90 Program
Impact Fas 123r Impact Performance Compensation
Income Taxes Insiders Substantial Control Over Delay Prevent Change Corporate
Intend Rely Parties Conduct Clinical Trials Drug Candidates License Patent Rights Party Vertex Pharmaceuticals Incorporated Not
Line Credit Facility List Subsidiaries
Long-term Incentives Managements Report Internal Control Over Financial Reporting
Manufacturing Supply Market Information
Marketable Securities Marketing Sales
Maryland Industrial Development Financing Authority Midfa Taxable Variable Material Modifications Rights Security Holders
Medarex Medarex Inc
Medimmune Merck Inc
Myc Program Need Substantial Additional Funding Not Available Acceptable Terms
New Drug Application Nominating Corporate Governance Committee
Not Able Recruit Retain Experienced Scientists Managers Need Not Able Successfully Manage Growth Business Materially Harmed
Not Manufacturing Capabilities Drug Candidates Notice Annual Meeting Proxy Statement
Novartis Novartis Institutes Biomedical Research Inc
Off-balance Sheet Arrangements Only Limited Experience Regulatory Affairs Affect Ability Time
Operating Capital Expenditure Requirements Operating Results Vary Significantly Period Result Decrease Price
Organization Principal Executive Offices Orphan Drug Designation Exclusivity
Other Collaborations Other Events
Other Fees Other Proposals
Other Regulations Other Relationships
Overview Parachute Limitations
Part Participation Financing
Participation Initial Public Offering Parties Challenge Validity Potential Patents Other Intellectual Property
Parties Engaged Produce Drug Candidates Clinical Fail Comply Patent Rights Licenses
Patents Licenses Proprietary Rights Pediatric Assessment
Pediatric Exclusivity Performance Graph
Personal Benefits Perquisites Pharmaceutical Product Regulation
Plan Benefits Policy Deductibility Executive Officer Compensation
Post Approval Phase Power Attorney
Pre-approval Services Preclinical Clinical Testing Time Consuming Expensive Uncertain Processes
Principal Accountant Fees Services Proceeds
Property Equipment Proposal Amendment Avalon Pharmaceuticals Inc 2005 Omnibus Long-term
Proposal Appointment Independent Registered Public Accounting Firm Proposal Election Directors
Provisions Charter Documents Delaware Law Make Acquisition Beneficial Proxies Voting Annual Meeting
Purpose Purpose Annual Meeting
Pursuant 906 Sarbanes-oxley Act 2002 Quarterly Results Fluctuate
Quorum Requirement Recent Accounting Pronouncements
Reclassification Recommendations Board Directors
Registration Rights Related Party Transaction Policy Procedures
Report Audit Committee Report Independent Registered Public Accounting Firm
Requirements Law Research Development Expense
Restricted Cash Investments Results Operations
Results Operations Financial Condition Revenue
Revenue Recognition Reverse Stock Split
Risks Related Common Stock Organizational Structure Risks Related Intellectual Property
Role Executives Establishing Executive Compensation Role Human Resources Department Compensation Consultant
Rule 14a-101 Rule 16b-3
Sales Marketing Distribution Experience Savings Plan
Securities Authorized Issuance Equity Compensation Plans Segment Information
Series Redeemable Convertible Preferred Stock Signatures
Sources Uses Cash Statements Operations
Stock Price Volatile Stock Retention Guidelines
Stock-based Compensation Stockholders
Stockholders Entitled Vote Stockholders Sharing Same Address
Strategy Subsequent Events
Survivin Program Table Contents
Technologies Terms Conditions Dividend Equivalent Rights
Terms Conditions Options Terms Conditions Performance Annual Incentive Awards
Terms Conditions Restricted Stock Units Terms Conditions Unrestricted Stock Awards
Therapeutic Antibodies Top Form
Trade Secrets Types Awards Available Grant Incentive Plan
Unable Accelerate Drug Discovery Process Unable Obtain Enforce Patent Protection Drug Candidates Business
Unregistered Sales Equity Securities Unsecured Financing
Vertex License Voting Proxies Vote Required
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki